{"entity":{"type":"insider","cik":"0001673228","url":"/insider/0001673228","json_url":"/insider/0001673228.json","name":"Canaan Partners X LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":10,"first":"2016-08-16","last":"2019-05-28","span_basis":"filed_date"},"name_variants":[{"name":"Canaan Partners X LLC","source":"filing","n_filings":10,"first_seen":"2016-08-16","last_seen":"2019-05-28"}],"transactions":[{"id":8429797,"accession":"0001567619-19-012237","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-19-012237","line_url":"/filing/0001567619-19-012237#line-3","is_derivative":false,"issuer_cik":"0001619859","issuer_name":"IDEAYA Biosciences, Inc.","issuer_ticker":"IDYA","issuer_name_source":null,"issuer_url":"/issuer/0001619859","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","shares_owned_after":2660713.0,"shares_owned_after_display":"2,660,713","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-28","filed_date":"2019-05-28","scope":"insider"},{"id":7810928,"accession":"0001123292-19-000749","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001123292-19-000749","line_url":"/filing/0001123292-19-000749#line-5","is_derivative":false,"issuer_cik":"0001619859","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001619859","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":750000.0,"total_display":"750,000.00","shares_owned_after":2254442.0,"shares_owned_after_display":"2,254,442","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-13","scope":"insider"},{"id":5964694,"accession":"0001209191-18-034203","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-034203","line_url":"/filing/0001209191-18-034203#line-4","is_derivative":false,"issuer_cik":"0001619859","issuer_name":"Iterum Therapeutics plc","issuer_ticker":"ITRM","issuer_name_source":null,"issuer_url":"/issuer/0001619859","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":506656.0,"shares_display":"506,656","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":6586528.0,"total_display":"6,586,528.00","shares_owned_after":1733170.0,"shares_owned_after_display":"1,733,170","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-05-30","scope":"insider"},{"id":6089628,"accession":"0000899243-18-013571","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-013571","line_url":"/filing/0000899243-18-013571#line-1","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38968.0,"shares_display":"38,968","price_per_share":6.0911,"price_display":"6.09","price_state":"stated","total_value":237357.9848,"total_display":"237,357.98","shares_owned_after":2116552.0,"shares_owned_after_display":"2,116,552","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-17","filed_date":"2018-05-21","scope":"insider"},{"id":6130947,"accession":"0000899243-18-013082","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-013082","line_url":"/filing/0000899243-18-013082#line-3","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29441.0,"shares_display":"29,441","price_per_share":6.456,"price_display":"6.46","price_state":"stated","total_value":190071.096,"total_display":"190,071.10","shares_owned_after":2155520.0,"shares_owned_after_display":"2,155,520","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-16","filed_date":"2018-05-16","scope":"insider"},{"id":6130942,"accession":"0000899243-18-013082","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-013082","line_url":"/filing/0000899243-18-013082#line-2","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57715.0,"shares_display":"57,715","price_per_share":6.4815,"price_display":"6.48","price_state":"stated","total_value":374079.7725,"total_display":"374,079.77","shares_owned_after":2184961.0,"shares_owned_after_display":"2,184,961","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-15","filed_date":"2018-05-16","scope":"insider"},{"id":6130939,"accession":"0000899243-18-013082","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-013082","line_url":"/filing/0000899243-18-013082#line-1","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":77591.0,"shares_display":"77,591","price_per_share":6.3696,"price_display":"6.37","price_state":"stated","total_value":494223.6336,"total_display":"494,223.63","shares_owned_after":2242676.0,"shares_owned_after_display":"2,242,676","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-14","filed_date":"2018-05-16","scope":"insider"},{"id":6250540,"accession":"0000899243-18-008487","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-008487","line_url":"/filing/0000899243-18-008487#line-1","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":59950.0,"shares_display":"59,950","price_per_share":20.706,"price_display":"20.71","price_state":"stated","total_value":1241324.7,"total_display":"1,241,324.70","shares_owned_after":2320267.0,"shares_owned_after_display":"2,320,267","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-23","filed_date":"2018-03-26","scope":"insider"},{"id":6250537,"accession":"0000899243-18-008349","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-008349","line_url":"/filing/0000899243-18-008349#line-3","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4759.0,"shares_display":"4,759","price_per_share":20.6205,"price_display":"20.62","price_state":"stated","total_value":98132.9595,"total_display":"98,132.96","shares_owned_after":2380217.0,"shares_owned_after_display":"2,380,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-22","filed_date":"2018-03-22","scope":"insider"},{"id":6250534,"accession":"0000899243-18-008349","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-008349","line_url":"/filing/0000899243-18-008349#line-2","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17699.0,"shares_display":"17,699","price_per_share":20.6072,"price_display":"20.61","price_state":"stated","total_value":364726.8328,"total_display":"364,726.83","shares_owned_after":2384976.0,"shares_owned_after_display":"2,384,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-21","filed_date":"2018-03-22","scope":"insider"},{"id":6250531,"accession":"0000899243-18-008349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-008349","line_url":"/filing/0000899243-18-008349#line-1","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17060.0,"shares_display":"17,060","price_per_share":20.606,"price_display":"20.61","price_state":"stated","total_value":351538.36,"total_display":"351,538.36","shares_owned_after":2402675.0,"shares_owned_after_display":"2,402,675","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-20","filed_date":"2018-03-22","scope":"insider"},{"id":6062290,"accession":"0000899243-18-007980","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-007980","line_url":"/filing/0000899243-18-007980#line-2","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13439.0,"shares_display":"13,439","price_per_share":20.5704,"price_display":"20.57","price_state":"stated","total_value":276445.6056,"total_display":"276,445.61","shares_owned_after":2419735.0,"shares_owned_after_display":"2,419,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-19","filed_date":"2018-03-19","scope":"insider"},{"id":6062287,"accession":"0000899243-18-007980","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-007980","line_url":"/filing/0000899243-18-007980#line-1","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6926.0,"shares_display":"6,926","price_per_share":20.5115,"price_display":"20.51","price_state":"stated","total_value":142062.649,"total_display":"142,062.65","shares_owned_after":2433174.0,"shares_owned_after_display":"2,433,174","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-16","filed_date":"2018-03-19","scope":"insider"},{"id":6510628,"accession":"0000899243-18-007581","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-007581","line_url":"/filing/0000899243-18-007581#line-3","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11751.0,"shares_display":"11,751","price_per_share":20.6383,"price_display":"20.64","price_state":"stated","total_value":242520.6633,"total_display":"242,520.66","shares_owned_after":2440100.0,"shares_owned_after_display":"2,440,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-15","filed_date":"2018-03-15","scope":"insider"},{"id":6510625,"accession":"0000899243-18-007581","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-007581","line_url":"/filing/0000899243-18-007581#line-2","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":20.77,"price_display":"20.77","price_state":"stated","total_value":4154.0,"total_display":"4,154.00","shares_owned_after":2451851.0,"shares_owned_after_display":"2,451,851","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-14","filed_date":"2018-03-15","scope":"insider"},{"id":6510619,"accession":"0000899243-18-007581","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-007581","line_url":"/filing/0000899243-18-007581#line-1","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Canaan Partners X LLC; CANAAN X L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1204.0,"shares_display":"1,204","price_per_share":20.842,"price_display":"20.84","price_state":"stated","total_value":25093.768,"total_display":"25,093.77","shares_owned_after":2452051.0,"shares_owned_after_display":"2,452,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-13","filed_date":"2018-03-15","scope":"insider"},{"id":2961129,"accession":"0001209191-16-137319","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-137319","line_url":"/filing/0001209191-16-137319#line-2","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"CANAAN X L.P.; Canaan Partners X LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":583333.0,"shares_display":"583,333","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":6999996.0,"total_display":"6,999,996.00","shares_owned_after":2453255.0,"shares_owned_after_display":"2,453,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-16","filed_date":"2016-08-16","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001676725","name":"IDEAYA Biosciences, Inc.","url":"/issuer/0001676725","role":"Ten percent owner","n_filings":1,"first_seen":"2019-05-28","last_seen":"2019-05-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001661059","name":"NextCure, Inc.","url":"/issuer/0001661059","role":"Ten percent owner","n_filings":1,"first_seen":"2019-05-13","last_seen":"2019-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001659323","name":"Iterum Therapeutics plc","url":"/issuer/0001659323","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2018-05-30","last_seen":"2018-05-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001377121","name":"Protagonist Therapeutics, Inc","url":"/issuer/0001377121","role":"Director, Ten percent owner","n_filings":7,"first_seen":"2016-08-16","last_seen":"2018-05-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001673228","retrieved_at":"2026-08-21T15:43:36+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}